Dyne Therapeutics announced proof-of-concept clinical data for genetic medicines to treat rare muscle diseases at the start of the year. The company raised $345 million in a stock offering, with plans to use the funds for clinical development of two clinical-stage programs, DYNE-101 and DYNE-251, both aimed at rare muscle diseases. The company’s DM1 therapy has shown positive results, with dose-dependent delivery of the treatment to muscle tissue and improvements in muscle function. Another therapy, DYNE-251, has also shown promising results, surpassing the effectiveness of a similar therapy by Sarepta. Dyne aims to develop a therapy pipeline for rare genetic diseases, with the potential for peak revenues in the billions.
Source link
Genetic Medicines Biotech Dyne Pulls In $345M for Clinical Tests of Muscle Drugs
